Literature DB >> 8374882

A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis.

L K Rocke1, C L Loprinzi, J K Lee, S J Kunselman, R K Iverson, G Finck, D Lifsey, K C Glaw, B A Stevens, A K Hatfield.   

Abstract

BACKGROUND: The authors previously reported that 30 minutes of oral cryotherapy inhibits 5-fluorouracil (5-FU)-induced stomatitis. The current trial was designed to determine whether a longer duration of cryotherapy would provide additional protection.
METHODS: This trial involved patients who were receiving their first course of a 5-FU plus leucovorin chemotherapy regimen, for which stomatitis is a major dose-limiting toxicity. These patients were randomized to receive either 30 or 60 minutes of oral cryotherapy given at around the same time as the 5-FU therapy.
RESULTS: A total of 178 evaluable patients were studied. Both cryotherapy groups had similar degrees of mucositis.
CONCLUSION: The authors continue to recommend the use of 30 minutes of oral cryotherapy for patients receiving bolus intensive courses of 5-FU-based chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8374882     DOI: 10.1002/1097-0142(19931001)72:7<2234::aid-cncr2820720728>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

Review 1.  Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J C de Graaf; J L Coenen; J R Brouwers
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Takehiko Mori; Rie Yamazaki; Yoshinobu Aisa; Tomonori Nakazato; Masumi Kudo; Tomoko Yashima; Sakiko Kondo; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Support Care Cancer       Date:  2006-01-28       Impact factor: 3.603

Review 3.  Interventions for preventing oral mucositis for patients with cancer receiving treatment.

Authors:  Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

Review 4.  [The therapeutic management of radiogenic oral mucositis].

Authors:  W Dörr; I Dölling-Jochem; M Baumann; T Herrmann
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

5.  Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Yoshinobu Aisa; Takehiko Mori; Masumi Kudo; Tomoko Yashima; Sakiko Kondo; Akihiro Yokoyama; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Support Care Cancer       Date:  2005-01-25       Impact factor: 3.603

Review 6.  The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis.

Authors:  Cesar A Migliorati; Loree Oberle-Edwards; Mark Schubert
Journal:  Support Care Cancer       Date:  2006-03-30       Impact factor: 3.603

Review 7.  Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy.

Authors:  Douglas E Peterson; Kerstin Ohrn; Joanne Bowen; Monica Fliedner; Judith Lees; Charles Loprinzi; Takehiko Mori; Anthony Osaguona; Dianna S Weikel; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2012-09-21       Impact factor: 3.603

Review 8.  Supportive cryotherapy: a review from head to toe.

Authors:  Kunal C Kadakia; Shaina A Rozell; Anish A Butala; Charles L Loprinzi
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

Review 9.  Management of oral mucositis in patients who have cancer.

Authors:  Rajesh V Lalla; Stephen T Sonis; Douglas E Peterson
Journal:  Dent Clin North Am       Date:  2008-01

10.  Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial.

Authors:  Anncarin Svanberg; Gunnar Birgegård; Kerstin Ohrn
Journal:  Support Care Cancer       Date:  2007-03-29       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.